---
layout: post
title: "Prospective Grant of an Exclusive Patent License: The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases"
date: 2026-02-04 21:48:43 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-12409
original_published: 2025-07-03 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases

**Published:** February 04, 2026 21:48 UTC
**Source:** Federal Register
**Original Published:** July 03, 2025 00:00 UTC
**Document Number:** 2025-12409

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents applications listed in the Supplementary Information section of this notice to Capstan Therapeutics, Inc. (Capstan), a company located in San Diego, California, the United States of America.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/07/03/2025-12409/prospective-grant-of-an-exclusive-patent-license-the-development-of-an-in-vivo-anti-cd19-chimeric)
- API: https://www.federalregister.gov/api/v1/documents/2025-12409

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
